Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma

Completed · Phase 2

Conditions studied: Sarcoma

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of exatecan mesylate in treating children who have relapsed or refractory rhabdomyosarcoma.

Key facts

Study ID

NCT00055939

Run by

Daiichi Sankyo

Starts

2003-01-01

Expected to finish

2006-04-01

Last updated by the study team

2012-05-16

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Colorado Cancer Center at University of Colorado Health Sciences Center — Denver, Colorado, United States
• Nemours Children's Clinic — Jacksonville, Florida, United States
• Cancer Institute of New Jersey — New Brunswick, New Jersey, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• St. Jude Children's Research Hospital — Memphis, Tennessee, United States
• Medical City Dallas Hospital — Dallas, Texas, United States
• Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas — Dallas, Texas, United States
• University of Texas - MD Anderson Cancer Center — Houston, Texas, United States
• Hospital for Sick Children — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.